FDA Grants Extra Patent Time for Mystery Drug GRAFAPEX
Published Date: 12/10/2025
Notice
Summary
The FDA has set the official review period for the drug GRAFAPEX, which helps the company extend its patent protection. This means the drug maker could get more time to exclusively sell GRAFAPEX, potentially affecting competition and profits. People can challenge the dates or the company’s effort in the review process by early to mid-2026.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA sets GRAFAPEX review period
FDA determined the regulatory review period for the drug GRAFAPEX (treosulfan) is 9,906 days total: 8,281 days in the testing phase and 1,625 days in the approval phase. The key dates are: IND effective December 10, 1997; NDA submitted August 11, 2020; and approval on January 21, 2025. This determination establishes the maximum potential length of a patent extension and the applicant is seeking 5 years of patent term extension.
Public can challenge dates and diligence
Anyone with knowledge that the published dates are incorrect may ask FDA for a redetermination by February 9, 2026, and any interested person may petition FDA regarding whether the applicant acted with due diligence during the regulatory review period by June 8, 2026. Instructions for electronic and written submissions are provided in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-22381 — Foreign-Trade Zone 40; Application for Subzone; Atlantic Veal & Lamb, LLC; Creston and Sterling, Ohio
Atlantic Veal & Lamb, LLC wants to join Foreign-Trade Zone 40 by adding two sites in Creston and Sterling, Ohio. This move could help the company save money on import taxes and speed up their business. Public comments are open until January 20, 2026, so folks have a chance to weigh in before the final decision.
Next: 2025-22383 — Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change of Amendments to Rules 915 and 916
NYSE American is updating its rules to make it easier to list options on Commodity-Based Trust Shares, just like Nasdaq did earlier this year. This change affects traders and investors who deal with these options and kicks in right away with no extra fees. It’s a smart move to keep NYSE American competitive and ready for more trading action.